Sun Pharma Advanced Research Company Limited Overview
Pro stress-test →Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products. The company is an India-based clinical-stage biopharmaceutical company that focuses on developing therapeutics to improve standards of care for patients worldwide, with therapeutic focus in the area of oncology, neurology and immunology.
Strategic Profile
Pro stress-test →The company is the first listed pharma R&D company out of India where founders still own 70% and continue to invest. Lead programs include vodobatinib (SCO-088) for refractory chronic myelogenous leukemia, vibozilimod (SCD-044) for autoimmune disorders, and SCD-153 for alopecia areata.
Competitive Landscape
Pro stress-test →Peers include Sun Pharmaceutical Industries Ltd, Divis Laboratories Ltd, Torrent Pharmaceuticals Ltd, Cipla Ltd, Lupin Ltd, Dr Reddy's Laboratories Ltd, and Zydus Lifesciences Ltd. SPARC is differentiated as a pure-play R&D company versus integrated pharma manufacturers.
Industry Context
Sun Pharma Advanced Research Company Limited operates in Pharmaceutical Research & Development / Clinical Stage Biopharmaceuticals.
Key facts
Founded: 2006 · Headquarters: Mumbai, India · Revenue: ₹7.86 crore Q2 FY26 (declining) · Market cap: ₹4,244-4,333 crore ($510-520M)